Technically Speakin...
Health Care: Drugs
Hemispherx Biopharma Inc. (HEB: AMEX)
$0.27 0.00 | 0.00%
06/04/12 - 01:03 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 3.10M | 2.92M | 58.07M | 6.12M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 897.00K | 787.00K | 0.00 | 864.00K |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 31.79M | 36.67M | 58.40M | 7.31M |
| Property, Plant & Equipment, Gross | 9.78M | 7.92M | 6.99M | 6.67M |
| Accumulated Depreciation & Depletion | 3.02M | 2.56M | 2.15M | 1.80M |
| Property, Plant & Equipment, Net | 6.76M | 5.36M | 4.84M | 4.88M |
| Intangibles | 863.00K | 794.00K | 830.00K | 969.00K |
| Other Non-Current Assets | 4.10M | 8.85M | 921.00K | 52.00K |
| Total Non-Current Assets | 11.73M | 15.01M | 6.59M | 5.90M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 43.51M | 51.68M | 64.99M | 13.21M |
| Accounts Payable | 1.68M | 1.33M | 1.29M | 791.00K |
| Short Term Debt | 1.74M | 61.00K | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 5.07M | 2.83M | 2.62M | 1.67M |
| Long Term Debt | 380.00K | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 2.80M | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 479.00K | 2.90M | 0.00 | 0.00 |
| Total Liabilities | 5.55M | 5.73M | 2.62M | 1.67M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 37.96M | 45.95M | 62.38M | 11.54M |
| Common Par | 136.00K | 135.00K | 133.00K | 79.00K |
| Additional Paid In Capital | 264.96M | 264.51M | 273.09M | 208.87M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -226.74M | -217.72M | -210.85M | -197.41M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -389.00K | -974.00K | 0.00 | 0.00 |
| Total Capitalization | 38.34M | 45.95M | 62.38M | 11.54M |
| Total Equity | 37.96M | 45.95M | 62.38M | 11.54M |
| Total Liabilities & Stock Equity | 43.51M | 51.68M | 64.99M | 13.21M |
| Total Common Shares Outstanding | 135.64M | 132.79M | 132.79M | 80.88M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 135.43M | 134.02M | 109.51M | 75.14M |
| Diluted Weighted Shares Outstanding | 135.43M | 134.02M | 109.51M | 75.14M |
| Number of Employees | 47 | 29 | 32 | 32 |
| Number of Part-Time Employees | 12 | 27 | 12 | 14 |
Portfolios with HEB
- Portfolio NameUser Type
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- ContributorBarron's Insider Purchases ...
- Usermaybe will work?
- UserTornado Portfolio
- Userjimb Portfolio 1
- Usergenomics
- User5for5
- Userjoe today
- UserNathan88
Latest HEB Headlines from TheStreet
- Hemisphrex Biopharma Announces Fiscal 2010 Year Results 03.29.11 | 01:03 pm
- Hemispherx Biopharma Reports On Annual Stockholder Meeting 03.22.11 | 02:03 pm
- Hemispherx Biopharma Announces 9th Clinical Investigators Conference: Ampligen Clinical Trials Highlighted 03.07.11 | 02:03 pm
- Chronix Biomedical And Hemispherx Biopharma Jointly File Patent Application For A Blood Test For Chronic Fatigue Syndrome (CFS) 03.03.11 | 10:03 am
- Hemispherx Biopharma Annual Meeting Set 02.24.11 | 08:02 am
- Hemispherx Biopharma, Inc. Announces It Has Scheduled Its 2010 Annual Stockholders' Meeting To Occur On March 17, 2011 In Remediation Of Notice From The NYSE Amex Of Non-Compliance With The Requirement To Hold Its Annual Stockholders' Meeting By The End Of 2010 02.23.11 | 01:02 pm
- Hemispherx Biopharma Appoints Senior Pharma Executive To Key Manufacturing Position 02.17.11 | 10:02 am
- Hemispherx Biopharma Announces US District Court Grants Final Approval Of Settlement Of Securities Class Actions 02.17.11 | 08:02 am
- FDA Authorizes Alferon LDO Clinical Study For Treatment And Prevention Of Influenza 01.04.11 | 10:01 am
- Hemispherx Biopharma, Inc. To Restate 2009 Financial Statements 12.28.10 | 04:12 pm
Press Releases for HEB
- Securities Class Action Filed By Shepherd, Finkelman, Miller & Shah, LLP On Behalf Of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 And November 2, 2009 - PR Newswire 12.08.09 | 04:12 pm
Partner Headlines for HEB
- Oink Oink: Profit From The Return Of Swine Flu - Benzinga 01.12.12 | 01:01 pm
- UPDATE 1-Hemispherx awarded $188 mln in "illegal" takeover suit - Reuters 08.18.10 | 12:08 pm
